吉西他滨联合PF 方案同期放化疗治疗晚期鼻咽 癌临床疗效分析

目的：探讨吉西他滨联合PF方案同期放化疗治疗72例晚期鼻咽癌的临床效果和安全性。方法将2012年2月至2012年12月我科收治的72例晚期鼻咽癌患者随机分成两组，两组接受放疗和PF方案治疗后，治疗组在此基础上给予静脉滴注吉西他滨，观察和比较两组治疗3个月后的临床疗效、生活质量的改善情况及不良反应的发生情况。结果放化疗3个月后，治疗组的近期疗效（89.2%）显著高于对照组近期疗效（71.4%），两组近期疗效相互比较差异具有统计学差异（P〈0.05）；治疗组KPS改善率为78.4％，而对照组KPS改善率为60％，治疗组显著高于对照组两组KPS改善率相互比较有显著统计学差异（P〈0.01），且治疗组子宫体积和肌瘤体积缩小幅度都明显优于对照组，相互比较差异有统计学意义（P〈0.01）；两组患者外周血白细胞减少、血小板减少、肝肾功能损害以及脱发的发生情况相互比较有统计学差异（P〈0.05）。结论吉西他滨联合PF方案同期放化疗治疗晚期鼻咽癌的近期临床疗效较单纯PF方案同期放化疗治疗晚期鼻咽癌，临床疗效确切更高，减轻毒副反应安全性更好，值得临床推广。

Analysis on Clinical Effects of Gemcitabine Combined with PF Regimen and Concurrent Chemoradiotherapy on Advanced Nasopharyngeal Carcinoma

Objective To explore the clinical effects and safety of Gemcitabine plus PF regimen and concurrent chemo-radiotherapy for patients with advanced nasopharyngeal carcinoma. Methods A total of 72 advanced nasopharyngeal car-cinoma patients who were enrolled between February 2012 and December 2012 in our departemnt were divided randomly into two groups. All of them were treated with radiotherapy as well as PF regimen. Patients in the treating group were added with gemcitabine. After three months＆#39; treatment, observe and compare the curative effects, improvement of life quality and adverse reactions. Results After treatment for three months, the short-term clinical effect of the treating group was 89.2%, superior to that （71.4%） of the control group, with statistical difference （P〈0.05）. The rate of KPS improvement was 78.4%in the treating group, but was 60%in the control group, and the difference was also significantly statistical （P〈0.01）. There were also statistical differences in leucopenia, thrombocytopenia, liver and kidney dysfunction, hair loss between the two groups （P〈0.05）. Conclusion Gemcitabine plus PF regimen and concurrent chemoradiotherapy had better curative effect and greater safety for advanced nasopharyngeal carcinoma than single PF regimen with concurrent chemoradiotherapy, and this combination treatment is worth advocating in clinic.